Serial Third Trimester Abdominal Circumference & Amniotic Fluid

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The purpose of this study us to compare the rate of prenatal identification of abnormal fetal growth or amniotic fluid between clinical evaluation of uterine size by symphysis fundal height (SFH) measurements versus point-of-care ultrasound (POC-US) evaluation of abdominal circumference (AC) and maximum vertical pocket (MVP).

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03230162` - Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment	Phase 3
Completed	`NCT03962153` - Ultrasonographic Parameters for Fetal Weight Prediction
Completed	`NCT03266198` - Fetal 3D Study (Fetal Body Composition and Volumes Study)

NCT number	NCT03857659
Study type	Interventional
Source	The University of Texas Health Science Center, Houston
Contact
Status	Terminated
Phase	N/A
Start date	April 5, 2019
Completion date	May 20, 2020

Serial Third Trimester Abdominal Circumference and Amniotic Fluid Measurements Versus Routine Care — STAR

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms